Palenzuela G et al. (2008) Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg 248: 836–841
Malignant germ-cell tumors of the ovary are rare and can be treated with cisplatin-based combination chemotherapy or ovariectomy. To achieve high cure rates for this disease a multidisciplinary approach is required. Palenzula et al. carried out a retrospective study to analyze outcomes in a cohort of patients who underwent surgical or medical management for malignant germ-cell tumors of the ovary.
The study included 60 patients treated for primary malignant germ-cell tumors of the ovary at two centers in France, between 1985 and 2003. The patient's case records were obtained and analyzed for information on diagnosis, surgery and medical decisions. A total of 38 tumors were stage I, and 22 were advanced. The mean follow-up period was 5.9 years. During follow-up, 16.7% of patients experienced relapse. In general, relapse occurred more frequently in patients with localized disease, possibly because those with advanced disease had received adjuvant chemotherapy. Overall survival at 5 years of follow-up was 96.7% and event-free survival was 79.2%. Patients who underwent postsurgical observation and those with yolk-sac tumor had an increased risk of relapse. The type of surgery or chemotherapy used had no prognostic value.
The authors conclude that outcomes of patients with malignant germ-cell ovarian tumors can be greatly influenced by accurate staging and adherence to surgical and medical guidelines.
Rights and permissions
About this article
Cite this article
Best practice in the management of malignant germ-cell tumors of the ovary. Nat Rev Clin Oncol 6, 63 (2009). https://doi.org/10.1038/ncponc1307
Issue Date:
DOI: https://doi.org/10.1038/ncponc1307